Standard Treatment Paths and Options

Treatment for POEMS syndrome is focused on one primary goal: stopping the abnormal plasma cells from producing the inflammatory signals that damage your body ^[1]. While your most bothersome symptoms might be nerve pain or swelling, treating the symptoms alone—such as using anti-VEGF drugs like bevacizumab—has generally proven ineffective in eradicating the disease ^[1]. Instead, your doctors will target the underlying plasma cell clone ^[2][3].

Choosing a Treatment Path

Your treatment plan is highly individualized. It is determined by how much of your body is affected by the abnormal plasma cells (found via scans and bone marrow biopsies), the severity of your organ involvement, and your overall fitness ^[4].

Localized Disease (Typically 1–3 Bone Lesions)

As a common decision aid, if the abnormal cells are confined to just one or a few areas—typically one to three sclerotic bone lesions with no abnormal cells found in the general bone marrow—doctors often recommend involved-site radiation therapy ^[1][5].

• The Goal: Use high-energy rays to destroy the localized group of plasma cells.
• The Outcome: For many patients with truly localized disease, radiation alone can cause symptoms to improve ^[4]. However, if the disease returns, systemic therapy may be needed.

Disseminated Disease (Widespread)

If there are multiple bone lesions, if abnormal plasma cells are found throughout the bone marrow, or if the disease is widespread, you will likely need systemic therapy (medication that travels through the bloodstream) ^[1][5].

The Path for Transplant-Eligible Patients

For patients who are healthy enough to undergo it, a standard treatment for disseminated POEMS is high-dose chemotherapy followed by an Autologous Stem Cell Transplant (ASCT) ^[6].

1. Stem Cell Collection: Your healthy blood-forming stem cells are collected and frozen.
2. High-Dose Chemotherapy: You receive a strong dose of a drug (melphalan) to kill the abnormal plasma cells.
3. The Rescue: Your frozen stem cells are returned to your body to help your bone marrow recover.

Efficacy and Risks: In cohort studies of selected, transplant-fit patients, ASCT has shown high success rates. In one large series of 239 patients, the five-year survival rate was approximately 93%, and many experienced significant neurological recovery, including regaining the ability to walk ^[6][7]. However, ASCT is an intensive procedure. Major risks include prolonged hospitalization, severe drops in blood counts (cytopenias), high risk of infection, mouth and gastrointestinal sores (mucositis), potential infertility, and a risk of treatment-related mortality ^[7]. Patients with severe fluid overload may require stabilization or a different induction therapy before they can safely undergo ASCT.

The Path for Transplant-Ineligible Patients

If a transplant is not the right choice for you—due to age, other health conditions, or severe organ involvement—other effective drug combinations are available ^[8].

• Lenalidomide and Dexamethasone: This oral combination has shown strong responses in trials (e.g., in a 41-patient study, 95% had neurological improvement) ^[8]. Safety Warning: Lenalidomide can substantially increase the risk of venous and arterial blood clots. You will need a specific thromboprophylaxis (clot prevention) plan, kidney monitoring, and strict pregnancy-prevention measures ^[8]. Dexamethasone (a steroid) also requires monitoring for high blood sugar, mood changes, and infection risk.
• Bortezomib and Dexamethasone: Another potent option. Safety Warning: Bortezomib can sometimes cause or worsen nerve damage (peripheral neuropathy), so doctors use it cautiously in POEMS patients. It also commonly requires antiviral medications to prevent shingles ^[9][10].

What to Expect During Recovery

Nerves heal very slowly. Even when treatments successfully lower your VEGF levels and suppress the plasma cells, it may take 6 to 12 months, or even longer, to feel the full benefit in your hands and feet ^[11][7]. Neurologic recovery can be partial, and residual deficits are common. Your care team will monitor your progress closely over time ^[6].